focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksProteome Regulatory News (PRM)

Share Price Information for Proteome (PRM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.90
Bid: 3.30
Ask: 4.50
Change: -0.10 (-2.50%)
Spread: 1.20 (36.364%)
Open: 4.00
High: 0.00
Low: 0.00
Prev. Close: 4.00
PRM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

License Agreement

9 Apr 2010 07:00

RNS Number : 9292J
Proteome Sciences PLC
09 April 2010
 



 

 

Proteome Sciences plc

ProteoPrep License agreement with Sigma-Aldrich

 

 

9th April, 2010 Proteome Sciences plc ("Proteome Sciences") is pleased to announce that it has entered into a non-exclusive license agreement with Sigma-Aldrich Corporation ("Sigma") under which Sigma will be able to continue selling products under Proteome's registered trademark ProteoPrep® in Europe, Japan and Australia. Sigma is the world's largest supplier of research biochemicals and organic chemicals with over one million customers.

 

There are currently eleven ProteoPrep® kits available from Sigma and the license will also include all future products sold under the ProteoPrep® trademark that contain chemicals and reagents for the disruption of cells, tissues or other biological material and the extraction of biological molecules like proteins, lipids and carbohydrates. It also covers methods and processes relating to assays for the diagnosis of diseases and chemical markers determining targets for drugs and for determining proteins and peptides by disruption of cells, tissues or other biological material. The license provides Proteome with a signature fee and royalties on all ProteoPrep® sales in the jurisdictions listed above.

 

Commenting on the license Christopher Pearce, Chief Executive of Proteome Sciences said:

 

"We are delighted to have concluded the license with Sigma-Aldrich Corporation for the ProteoPrep® trademark and look forward to receiving this new stream of revenue from royalties generated by their successful and expanding range of ProteoPrep® products."

 

 

 

- End -

 

 

For further information please contact:

 

Proteome Sciences plc

www.proteomics.com Tel: +44 (0)1932 865065

Christopher Pearce, Chief Executive Officer christopher.pearce@proteomics.com 

James Malthouse, Finance Director james.malthouse@proteomics.com 

Dr. Ian Pike, Chief Operating Officer ian.pike@proteomics.com 

 

Nominated Adviser

Singer Capital Markets Limited

Shaun Dobson/Claes Spång

Tel: +44 (0)20 3205 7500

 

Public Relations

IKON Associates Redleaf Communications Limited

Adrian Shaw Anna Dunkin/Lucy Salaman

Tel: +44 (0)1483 535102 Tel: +44 (0)20 7566 6700

Mobile: +44 (0)7979 900733 Email: proteome@redleafpr.com 

Email: adrian@ikonassociates.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
STRLLFLRSDITIII
Date   Source Headline
5th Nov 20217:00 amRNSPRM,INmune Bio presenting biomarker discovery data
3rd Nov 20214:41 pmRNSSecond Price Monitoring Extn
3rd Nov 20214:36 pmRNSPrice Monitoring Extension
26th Aug 20214:40 pmRNSSecond Price Monitoring Extn
26th Aug 20214:36 pmRNSPrice Monitoring Extension
29th Jul 20217:00 amRNSInterim Results
15th Jul 20214:41 pmRNSSecond Price Monitoring Extn
15th Jul 20214:35 pmRNSPrice Monitoring Extension
18th Jun 20211:14 pmRNSLoan amendment
8th Jun 202112:54 pmRNSGrant of Options and PDMR/director shareholdings
19th May 20216:01 pmRNSIssuance of key TMT Patent
18th May 20219:48 amRNSChange of Registered Office
12th May 20214:36 pmRNSPrice Monitoring Extension
7th May 20214:41 pmRNSSecond Price Monitoring Extn
7th May 20214:36 pmRNSPrice Monitoring Extension
6th May 20214:41 pmRNSSecond Price Monitoring Extn
6th May 20214:35 pmRNSPrice Monitoring Extension
5th May 20214:41 pmRNSSecond Price Monitoring Extn
5th May 20214:35 pmRNSPrice Monitoring Extension
5th May 202111:57 amRNSResult of AGM
5th May 202111:00 amRNSAGM Statement
27th Apr 20214:40 pmRNSSecond Price Monitoring Extn
27th Apr 20214:35 pmRNSPrice Monitoring Extension
19th Apr 20215:25 pmRNSDirector/PDMR Shareholding
14th Apr 202112:18 pmRNSDirector/PDMR Shareholding
7th Apr 20214:40 pmRNSSecond Price Monitoring Extn
7th Apr 20214:35 pmRNSPrice Monitoring Extension
1st Apr 202112:48 pmRNSHolding(s) in Company
1st Apr 20219:34 amRNSInvestor Presentation
1st Apr 20217:40 amRNSFinal Results
30th Mar 20217:00 amRNSLoan Amendment
29th Mar 20216:21 pmRNSHolding(s) in Company
26th Mar 20217:00 amRNSTrading Update and Notice of Results
25th Jan 20217:00 amRNSYear End Trading Update
18th Jan 20217:00 amRNSHolding(s) in Company
15th Sep 20204:35 pmRNSDirector/PDMR Shareholding
14th Sep 20207:00 amRNSAppointment of Chief Executive Officer
10th Aug 20207:00 amRNSInterim Results
27th Jul 202011:53 amRNSHolding(s) in Company
7th Jul 20201:47 pmRNSDirector/PDMR Shareholding
2nd Jul 20204:08 pmRNSDirector/PDMR Shareholding
26th Jun 202011:45 amRNSResult of AGM
26th Jun 202011:00 amRNSAGM Statement
2nd Jun 20207:00 amRNSNotice of Annual General Meeting
30th Apr 20204:53 pmRNSHolding(s) in Company
28th Apr 202011:16 amRNSResponse to Share Price Movement
20th Apr 20207:00 amRNSPosting of Results, AGM update and loan amendment
14th Apr 20207:00 amRNSFinal Results
30th Mar 20207:00 amRNSNotice of Results
16th Mar 20207:00 amRNSNotice of Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.